Business Context and Reporting Period
Anika Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2005. The company develops, manufactures, and commercializes therapeutic products based on hyaluronic acid (HA) for bone, cartilage, and soft tissue protection. Key marketed products include ORTHOVISC (osteoarthritis), HYVISC (equine osteoarthritis), and ophthalmic viscoelastic products (AMVISC, STAARVISC, ShellGel). The company operates as a single reportable segment with substantial operations in the United States.
Key Financial Metrics
| Metric (Nine Months Ended Sep 30, 2005) | Value |
|---|---|
| Total Revenue | $24,369,000 |
| Net Income | $5,071,000 |
| Gross Profit | $15,491,000 (64% margin) |
| Operating Income | $7,693,000 |
| Cash and Cash Equivalents | $45,872,000 |
| Working Capital | $46,285,000 |
| Total Liabilities | $25,757,000 |
| Stockholders' Equity | $37,061,000 |
Note: The company reported no long-term debt. Liabilities consist primarily of deferred revenue ($22,397,000 total).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 29.6% year-over-year for the nine months ended September 30, 2005 ($24.4M vs. $18.8M). This was driven by a significant increase in license, milestone, and contract revenue ($8.6M vs. $2.0M), partially offset by a 6.3% decline in product revenue ($15.8M vs. $16.8M).
- Product Mix Shift: Ophthalmic product revenue increased 2% year-over-year, recovering from a voluntary product recall in Q2 2005. ORTHOVISC product revenue decreased 17% due to inventory destocking by partner Johnson & Johnson following a large initial build-up in 2004.
- Contract Revenue Spike: The company recognized $3.4M in contract revenue in Q3 2005 related to the termination of its agreement with OrthoNeutrogena, including a $3.1M termination payment.
- Profitability: Net income for the nine months was $5.1M, compared to $9.4M in the prior year. The prior year included a one-time $7.0M tax benefit from the release of a valuation allowance, which did not recur in 2005.
- Cash Flow: Net cash provided by operating activities decreased to $7.1M from $18.6M in the prior year, primarily due to the recognition of deferred revenue from the Ortho Biotech milestone payments received in 2004.
Guidance, Outlook, and Risks
- Outlook: Management expects international sales of ORTHOVISC to continue growing in 2005, though at a lower rate than the first nine months. Ophthalmic sales for 2005 are expected to be below 2004 levels due to the expiration of the agreement with Advanced Medical Optics, partially offset by increased sales to Bausch & Lomb.
- Regulatory Status: The company filed a PMA application with the FDA for its Cosmetic Tissue Augmentation (CTA) product in September 2005. A new J-code (J7318) for ORTHOVISC reimbursement was issued by CMS for use starting January 1, 2006, though the impact on revenue remains uncertain.
- Capital Expenditures: The company expects to incur approximately $3.5M in capital expenditures for facility upgrades and CTA manufacturing equipment, with $1.6M expected in 2005 and the balance in early 2006.
- Accounting Changes: The company plans to adopt SFAS 123(R) prospectively in Q1 2006, which will result in non-cash stock-based compensation charges expected to materially impact future results.
- Risks: Key risks include dependence on a small number of customers (Bausch & Lomb and Johnson & Johnson accounted for significant revenue), potential delays in FDA approvals for new products, and the impact of reimbursement code changes on ORTHOVISC sales.
Investor Verification Checklist
- Deferred Revenue Amortization: Verify the recognition schedule of the $27M upfront/milestone payments from Ortho Biotech, which are being amortized over 10 years.
- Customer Concentration: Confirm the stability of relationships with Bausch & Lomb (62% of Q3 product revenue) and Johnson & Johnson, given the expiration of the Advanced Medical Optics contract.
- Reimbursement Impact: Assess the potential financial impact of the new J7318 reimbursement code effective January 2006 on ORTHOVISC sales.
- Stock-Based Compensation: Monitor the adoption of SFAS 123(R) in 2006 and its effect on reported net income.
- Product Recall Costs: Review the final costs associated with the Q2 2005 ophthalmic product recall and any lingering inventory impacts.